Geographical differences in attention deficit hyperactivity disorder treatment rates across the UK
Blandine French , James Davies , Chris Williams , Amanda Kirby
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004163
Aim: Attention deficit hyperactivity disorder (ADHD) is a common condition impacting approximately 5% of children and 3–4% of adults in the United Kingdom (UK). While it cannot be cured, treatment has been shown to positively impact the difficulties associated with ADHD. However, ADHD is widely underdiagnosed and undertreated in the UK. This paper reports the results of a model developed to estimate pharmacological treatment rates by area across National Health Service (NHS) integrated care systems (ICSs) in England, health boards in Scotland and Wales, and health & social care trusts (HSCTs) in Northern Ireland. Methods: The model used the UK general population and ADHD prevalence data to estimate the number of patients with ADHD in each area. Prescription data for medicines licensed for the treatment of ADHD were then used to estimate the number of patients who are untreated and treated, and the percentage treatment rates by area. The analysis was descriptive, focusing on quantifying geographic variation in treatment rates. Results: Nationally, the estimated proportions of children and young people (CYP; 5–17 years) and adults (18–65 years) treated were 26.6% and 15.6%, respectively, of the expected ADHD populations. Treatment rates by ICS or health board in England, Scotland, and Wales ranged from 11.7% to 60.6% for the CYP population and 8.6% to 24.8% for the adult population (data for Northern Ireland were not available by age group). Overall treatment rates (ages 5–65 years) in Northern Ireland ranged from 6.7% in the lowest-ranking HSCT to 31.1% in the highest-ranking HSCT. Conclusions: In the UK, there is currently a high degree of geographic variation across all NHS systems and a generally low level of treatment of ADHD, especially in adults. Up to a 4.6-fold difference in pharmacological treatment rates was observed between NHS service provider areas.
ADHD / treatment / treatment rates / variation model / healthcare services
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
CKS via NICE is only available to eligible users within the UK [Internet]. NICE; c2026 [cited 2026 Jun 9]. Available from: https://cks.nice.org.uk/topics/attention-deficit-hyperactivity-disorder/background-information/prevalence/ |
| [5] |
|
| [6] |
|
| [7] |
French B, Nalbant G, Wright H, Sayal K, Daley D, Groom MJ, |
| [8] |
Wright N, Moldavsky M, Schneider J, Chakrabarti I, Coates J, Daley D, |
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
Boland H, DiSalvo M, Fried R, Woodworth KY, Wilens T, Faraone SV, |
| [15] |
Report of the independent ADHD Taskforce [Internet]. [cited 2026 Jun 12]. Available from: https://www.england.nhs.uk/publication/report-of-the-independent-adhd-taskforce/ |
| [16] |
NHS to launch cross-sector ADHD taskforce to boost care for patients in England [Internet]. [cited 2026 Jun 12]. Available from: https://www.england.nhs.uk/2024/03/nhs-to-launch-cross-sector-adhd-taskforce-to-boost-care-for-patients-in-england/ |
| [17] |
Vibert S. Your Attention Please: The Social and Economic Impact of ADHD [Internet]. Demos. Some rights reserved; c2018 [cited 2026 Jun 12]. Available from: https://demos.co.uk/wp-content/uploads/2018/12/Your-Attention-Please-the-social-and-economic-impact-of-ADHD-.pdf |
| [18] |
|
| [19] |
Daley D, Jacobsen RH, Lange AM, Sørensen A, Walldorf J. The economic burden of adult attention deficit hyperactivity disorder: A sibling comparison cost analysis. Eur Psychiatry. 2019; 61: 41-8. |
| [20] |
Clark DM. Implementing NICE guidelines for the psychological treatment of depression and anxiety disorders: The IAPT experience. Int Rev Psychiatry. 2011; 23: 318-27. |
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
Health geographies population estimates (Accredited official statistics) [Internet]. [cited 2025 Feb 3]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/clinicalcommissioninggroupmidyearpopulationestimates |
| [26] |
Health Board (2019) Population Estimates [Internet]. [cited 2025 Feb 3]. Available from: https://www.opendata.nhs.scot/dataset/population-estimates/resource/27a72cc8-d6d8-430c-8b4f-3109a9ceadb1 |
| [27] |
2022 Mid-Year Population Estimates for Small Geographical Areas within Northern Ireland [Internet]. NISRA; [cited 2025 Feb 3]. Available from: https://www.nisra.gov.uk/publications/2022-mid-year-population-estimates-small-geographical-areas |
| [28] |
Chang Z, Lichtenstein P, |
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
Update on ADHD Medication Shortage [Internet]. NHS Cheshire and Merseyside; [cited 2026 Jun 9]. Available from: https://www.cheshireandmerseyside.nhs.uk//your-health/prescribing/update-on-adhd-medication-shortage/ |
| [36] |
Statement on shortage of ADHD medication [Internet]. Royal College of Psychiatrists; c2026 [cited 2026 Jun 26]. Available from: https://www.rcpsych.ac.uk/news-and-features/latest-news/detail/2023/10/19/statement-on-shortage-of-adhd-medication |
| [37] |
Choice [Internet]. [cited 2026 Jun 26]. Available from: https://www.england.nhs.uk/personalisedcare/choice/ |
| [38] |
|
/
| 〈 |
|
〉 |